Condition: Urothelial Cancer · Bladder Cancer · Sponsor: Daiichi Sankyo
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommended Phase 3 dose (RP3D) will be identified when the data allow sufficient assessment of activity, safety, and tolerability. The Phase 3 part will start contingent upon the assessment in the Phase 2 part, taking into consideration the totality of information.
This description comes directly from the study's public registry record.
Contact for Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Research Site | Fullerton, California, United States | Active Not Recruiting |
| Research Site | Glendale, California, United States | Active Not Recruiting |
| Research Site | La Jolla, California, United States | Active Not Recruiting |
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | Orange, California, United States | Active Not Recruiting |
| Research Site | San Francisco, California, United States | Active Not Recruiting |
| Research Site | Aurora, Colorado, United States | Active Not Recruiting |
| Research Site | Orange City, Florida, United States | Active Not Recruiting |
| Research Site | St. Petersburg, Florida, United States | Active Not Recruiting |
| Research Site | Tamarac, Florida, United States | Active Not Recruiting |
| Research Site | Atlanta, Georgia, United States | Active Not Recruiting |
| Research Site | Locust Grove, Georgia, United States | Active Not Recruiting |
+ 88 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07129993